CHINA – Guardant Health has partnered with Adicon, an independent clinical laboratory company based in China, to offer Guardant’s comprehensive genomic profiling (CGP) cancer tests to biopharmaceutical companies conducting clinical trials in China.
Increasing incidence rates have made cancer a high priority in China and have led to a rising number of clinical trials in the region.
The collaboration includes Guardant Health’s liquid biopsy technologies, the Guardant360 and GuardantOmni tests, and the Guardant360 TissueNext tissue-based biopsy designed to analyze the genomic profile of individual solid cancerous tumor and match patients up with the proper therapy or enrollment into a study.
It also includes Guardant Reveal, a blood-only test developed to detect residual disease and monitor recurrence of cancer among patients treated for the disease.
The companies said that Guardant Reveal will also be offered to drugmakers working in the early stages of cancer research and development.
Helmy Eltoukhy, Guardant Health co-CEO noted that the partnership with Adicon marks another important milestone for Guardant Health, and will bring our comprehensive genomic profiling tests and services to researchers in China.
Even more, the partnership transforms Adicon’s ability to serve biopharmaceutical customers and beyond, according to Ling Yang, Adicon’s chairwoman.
The collaboration includes Guardant Health’s liquid biopsy technologies, the Guardant360 and GuardantOmni tests, and the Guardant360 TissueNext tissue-based biopsy designed to analyze the genomic profile of individual solid cancerous tumor and match patients up with the proper therapy or enrollment into a study.
Lawrence Wang, CFO at Adicon said, “With our CAP accredited laboratory in Shanghai, we are delighted to partner with Guardant Health to make its cancer tests available for biopharmaceutical partners in China.”
Other recent Guardant Health news
The move follows the regulatory approval of the Guardant360 CDx test in Japan this past March.
That approval included a green light as a blood-based companion diagnostic to identify patients with microsatellite instability-high cancers, including those with solid tumors that may benefit from Merck’s Keytruda, as well as people with advanced colorectal cancer who may benefit from Bristol Myers Squibb’s Opdivo.
The partnership with Adicon also follows Guardant’s announcement June 13 that the company has purchased the remaining shares of Guardant Health AMEA, which had been held by SoftBank and its affiliates, giving the company full control over its operations throughout the Asia, Middle East, and Africa (AMEA).
The company had previously established the Guardant Health AMEA joint venture in May 2018 in an effort to expand commercialization of its liquid biopsy cancer tests across the region. Guardant paid about US$177.8 million to buy out SoftBank and its affiliates.
“By acquiring the remaining shares of Guardant Health AMEA, we can focus on creating a unified and centralized global organization that delivers on our promise to help conquer cancer and improve patient outcomes,” Eltoukhy said.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE.
